This week's Fierce Biotech is brought to you by Hub Organoids.

Webinar: Mini-Organs, Major Breakthroughs: How Hub Organoids Are Accelerating Oncology Drug Development

Tuesday, May 14, 2024 | 9:30am ET/ 6:30am PT

Patient-derived organoids are viewed as the gold standard in bridging the gap between the lab and the clinic. Advancements in HUB Organoid Technology, using patient material to generate “mini-organs” in a dish, have revolutionized in vitro predictivity over conventional 2D cell cultures and animal models, which fail to recapitulate patient tumor biology either due to lack of cellular complexity or fundamental species differences.

Save Your Spot!

Register for this webinar to explore:

What makes HUB Organoids a superior 3D in vitro system for oncology drug development
The application of 3D organoids and organoid-based co-cultures in oncology drug development
Compelling case studies showcasing the efficacy of HUB's organoid screening platform in guiding the development of clinical candidates

You are currently subscribed as newsletter@newslettercollector.com
If you no longer wish to receive promotions from Fierce Biotech, simply unsubscribe.
Refer to our Privacy Policy.

Fierce Biotech is a division of Questex LLC.
685 3rd Ave 21st Floor New York, NY 10017
© 2024 Questex LLC. All Rights Reserved.
Reproduction in whole or in part is prohibited without written permission.